Evaluation of the most commonly used (semi-) quantitative parameters of 18F-FDG PET/CT to detect malignant transformation of neurofibromas in neurofibromatosis type 1

被引:12
作者
Brinkman, Marloes [1 ]
Jentjens, Sander [2 ,6 ]
Boone, Kitty [2 ]
Anten, Monique [1 ,3 ]
Stumpel, Constance T. R. M. [3 ,4 ]
Nelemans, Patty J. [5 ]
van Kroonenburgh, Marinus J. P. G. [2 ,3 ]
机构
[1] Maastricht Univ, Med Ctr, Dept Neurol, Maastricht, Netherlands
[2] Maastricht Univ, Med Ctr, Dept Radiol & Nucl Med, P Debyelaan 25, NL-6229 HX Maastricht, Netherlands
[3] Maastricht Univ, Med Ctr, Neurofibromatosis Expert Team, Maastricht, Netherlands
[4] Maastricht Univ, Med Ctr, Dept Clin Genet, Maastricht, Netherlands
[5] Maastricht Univ, Med Ctr, Dept Epidemiol, Maastricht, Netherlands
[6] Catharina Hosp, Dept Nucl Med, Eindhoven, Netherlands
关键词
malignant peripheral nerve sheath tumor; neurofibromatosis type 1; PET/CT; POSITRON-EMISSION-TOMOGRAPHY; NERVE SHEATH TUMORS; CEREBRAL GLUCOSE-METABOLISM; UPTAKE VALUE SUV; TO-LIVER RATIO; FDG-PET; SARCOMATOUS TRANSFORMATION; PLEXIFORM NEUROFIBROMAS; SOLITARY NEUROFIBROMA; COMPUTED-TOMOGRAPHY;
D O I
10.1097/MNM.0000000000000889
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
In patients with neurofibromatosis type 1, transformation of neurofibromas into a malignant peripheral nerve sheath tumor (MPNST) is a severe complication of the disease. Fluorine-18-fluorodeoxyglucose PET/computed tomography (PET/CT) is a viable option for detecting malignant tumors in neurofibromatosis type 1 patients. The aim of this review was to assess the diagnostic performance of the most frequently used parameters of PET/CT in detecting MPNST. An extensive computer search was performed using the Cochrane Library, Pubmed, and Medline/Embase databases. Two reviewers independently extracted data of relevant studies and assessed the methodological quality (QUADAS-2). The diagnostic performance of PET/CT parameters in individual studies was determined by calculating a diagnostic odds ratio (DOR) using the absolute numbers of true-positive, true-negative, false-positive, and false-negative test results. A total of eight studies were included, of which three evaluated the standardized uptake value as a diagnostic parameter, two assessed the tumor-to-liver (T/L) ratio, and three articles described both parameters. The cut-off values for maximum standardized uptake value (SUVmax) ranged from 3.2 to 4.5; for the T/L ratio, the cut-off values were between 1.0 and 4.3. The sensitivity and specificity ranged from 90 to 100% and from 80 to 100%, respectively (SUVmax). T/L ratios were associated with 92-100% sensitivity and 72-94% specificity. The corresponding DORs ranged from 57 to 145 (SUVmax) and 35 to 655 (T/L ratio). Both the SUV and the T/L ratio are associated with high sensitivity combined with acceptable specificity in detecting MPNST. There is a tendency toward higher DORs using the T/L ratio, but the number of studies is limited. Copyright (C) 2018 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:961 / 968
页数:8
相关论文
共 136 条
[81]  
Mantaka P, 1999, ANTICANCER RES, V19, P4443
[82]   Gastrinoma and neurofibromatosis type 2: the first case report and review of the literature [J].
Massironi, Sara ;
Zilli, Alessandra ;
Rossi, Roberta Elisa ;
Cavalcoli, Federica ;
Conte, Dario ;
Peracchi, Maddalena .
BMC GASTROENTEROLOGY, 2014, 14
[83]  
Mautner VF, 2007, ANTICANCER RES, V27, P1819
[84]   Critical role of PTEN for development and progression of nerve sheath tumors in neurofibromatosis type 1 [J].
Mawrin, Christian .
FUTURE ONCOLOGY, 2010, 6 (04) :499-501
[85]   18-Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) Evaluation of Nodular Lesions in Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas (PN) or Malignant Peripheral Nerve Sheath Tumors (MPNST) [J].
Meany, Holly ;
Dombi, Eva ;
Reynolds, James ;
Whatley, Millie ;
Kurwa, Ambereen ;
Tsokos, Maria ;
Salzer, Wanda ;
Gillespie, Andrea ;
Baldwin, Andrea ;
Derdak, Joanne ;
Widemann, Brigitte .
PEDIATRIC BLOOD & CANCER, 2013, 60 (01) :59-64
[86]   Utility of positron emission tomography for tumour surveillance in children with neurofibromatosis type 1 [J].
Moharir, Mahendranath ;
London, Kevin ;
Howman-Giles, Robert ;
North, Kathryn .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 (07) :1309-1317
[87]   Peripheral and cranial nerve sheath tumors [J].
Mrugala, MM ;
Batchelor, TT ;
Plotkin, SR .
CURRENT OPINION IN NEUROLOGY, 2005, 18 (05) :604-610
[88]   Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation [J].
Nielsen, GP ;
Stemmer-Rachamimov, AO ;
Ino, Y ;
Moller, MB ;
Rosenberg, AE ;
Louis, DN .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (06) :1879-1884
[89]   Correlations between F-18 FDG PET/CT and pathological findings in soft tissue lesions [J].
Nose, Hayato ;
Otsuka, Hideki ;
Otomi, Yoichi ;
Terazawa, Kaori ;
Takao, Shoichiro ;
Iwamoto, Seiji ;
Harada, Masafumi .
JOURNAL OF MEDICAL INVESTIGATION, 2013, 60 (3-4) :184-190
[90]   Young Australian adults with NF1 have poor access to health care, high complication rates, and limited disease knowledge [J].
Oates, Emily C. ;
Payne, Jonathan M. ;
Foster, Sheryl L. ;
Clarke, Nigel F. ;
North, Kathryn N. .
AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2013, 161A (04) :659-666